AMEX Accepts Lorus' Plan to Meet AMEX's Continued Listing Standards
... TORONTO, May 6 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. ("Lorus" or the "Company") (TSX:...y the end of the extension period. About Lorus lorus is a biopharmaceutical company focused on the rese...forts and an acquisition and in-licensing program, lorus is building a portfolio of promising anticancer dr...Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
... TORONTO, Sept. 19 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biophar...lified individuals to our Board. They all bring to lorus an exceptional level of knowledge and experience i...g with them, to enhance shareholder value." About lorus ...Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
... TORONTO, July 21 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. (Lorus), a biopharmaceutical com...Phase I clinical study in cancer indications. lorus intends to submit an IND for LOR-253 by the Q...srael. Under the terms of the licensing agreement, lorus is entitled to receive payments in excess of ...Lorus Therapeutics Receives $600 Thousand From Escrow Account
... TORONTO, July 16 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a b...ce on forward-looking statements due to the inherent uncertainty therein. lorus Therapeutics Inc.'s recent press releases are available through the Company...Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
... TORONTO, July 9 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" o...tected in Mexico under an earlier patent issued to lorus in 2003. Virulizin(R) has demonstrated significa...locally advanced and metastatic pancreatic cancer. lorus has reported that the overall survival data in thi...Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
... TORONTO, May 5 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP),...Lorus' senior management team. Dr. Babaei joined lorus in 2006, where he has held the progressive positio...-for-profit organizations. Dr. Lee has been with lorus for ten years, most recently serving as the Direct...Lorus initiates development program exploring novel route of administration for LOR-2040
... TORONTO, April 22 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical c...se of LOR-2040 in the treatment of bladder cancer. lorus intends to submit the IND during Q3, 2008, followi...r growth and metastatic potential. About Lorus lorus is a biopharmaceutical company focused on the rese...Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
...CR) - TORONTO, April 16 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP),...esented on April 16, 2008. In this presentation, lorus provided data on the preclinical development of LO...nked to the development of cancer. About Lorus lorus is a biopharmaceutical company focused on the rese...Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
... TORONTO, Jan. 22 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biophar...rofessional skills and integrity." About Lorus lorus is a biopharmaceutical company focused on the rese...forts and an acquisition and in-licensing program, lorus is building a portfolio of promising anticancer dr...Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
... TRIAL TORONTO, Aug. 29 /PRNewswire-FirstCall/ - lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP),...fficacy evaluation in a larger patient population. lorus expects the clinical trial to be completed by the end of 2008. The decision by lorus to advance clinical development of GTI-2040 is bas...